6/6 What are your thoughts?. IRs using #AI will replace those who don’t! Save time, get smarter, & become AI enhanced! Be sure to subscribe our newsletter:. Follow us on LinkedIn: #VIR #iRads @CVIR_Journal @cvirendo @cirsesociety.

5/6 📌 Conclusion: This study demonstrates high 12-month primary patency (89.5%) and low complication rates using retrievable scaffold therapy with sirolimus-coated balloon angioplasty for infrapopliteal lesions. Read more here:

4/6 By 12 months:. 📈 89.5% primary patency.✅ 68.2% improved Rutherford class.🦶 90% low/very low amputation risk (WIfI scores).✨ No additional major amputations or target lesion revascularizations. #VascularHealth #PatientOutcomes

3/6 Results at 6 months:. 🔹 11.5% primary safety events (1 mortality, 1 major amputation, 1 target lesion revascularization).🔹 Late lumen loss: 0.7±0.7 mm.🔹 Negligible acute vessel recoil (2.4 mm to 2.3 mm)

2/6 The DEEPER LIMUS study focused on patients with Rutherford class 3 to 5 infrapopliteal artery disease. Participants underwent vessel preparation with retrievable scaffold therapy followed by sirolimus-coated balloon angioplasty 💉. #InterventionalRadiology #VascularSurgery

1/6 🚨 89.5% primary patency achieved in retrievable scaffold therapy with sirolimus-coated balloon angioplasty for infrapopliteal lesions! 🩺🌟. Check out the latest findings from @CVIR_Journal in their DEEPER LIMUS study👇. #Infrapopliteal #Angioplasty #VascularHealth

5/5 What are your thoughts?. Stay at the forefront with #AI-enhanced #IR! Follow us for the latest research updates:. Follow us on LinkedIn: #VIR #InterventionalRadiology #IRadPulse @cvirendo @cirsesociety.

4/5 📌 Conclusion: In this small study, PBNA achieved 100% technical success with no reported complications, bile leakages, or re-occlusions during a median follow-up of 2.8 years. Full study: #BiliarySurgery #Transplantation #MedTwitter.

3/5 Key Findings:. - Technical success: 100%.- PTBDs removed median of 65 days post-procedure.- Median follow-up: 2.8 years.- Outcomes: No bile leakages or re-occlusions observed.- Complications: None reported. #PatientOutcomes #Safety

2/5 Study Details:. - Participants: 4 patients (mean age 56).- Background: Right posterior bile duct exclusion and bile leakage after liver/pancreatic surgery or liver transplant.- Method: Fluoroscopy-guided PBNA followed by PTBD. #Hepatology

1/5 🚨 100% technical success in performing percutaneous biliary neo-anastomosis (PBNA) with fluoroscopy guidance!👇. Check out this recent study from @CVIR_Journal exploring the safety and effectiveness of PBNA for challenging biliary conditions 🧵. #BiliaryIntervention

6/6 What are your thoughts?. Stay up-to-date with the latest in #VIR research. Subscribe to our newsletter: Follow us on LinkedIn: #TransplantSpecialists #InnovativeCare @cvirendo @cirsesociety.

5/6 📌 Conclusion: In this study, TACE with doxorubicin-eluting microspheres showed low HCC recurrence post-transplant, with lesion characteristics dictating recurrence risks. Dive deeper into the study: #MedicalResearch #InterventionalRadiology.

4/6 Prognostic Insights:. 🔑 Number and total size of HCC lesions at diagnosis and explant:. • Key risk factors for recurrence. • Number of lesions (p = 0.0088) & largest tumor size (p = 0.0179). #CancerResearch #Hepatology #VascularHealth.

3/6 Results:. 📌 Post-transplant HCC recurrence:. • Bridging: 1 patient (3%). • Downstaging: 4 patients (23.5%). 📌 Disease-free survival at 5 years:. • Bridging: 86%. • Downstaging: 65% (p < 0.05). #LiverDisease #Chemoembolization

2/6 Study Focus:. 🔍 286 patients undergoing liver transplantation for cirrhosis and early HCC (2006-2021).🔍 53 received neoadjuvant TACE with doxorubicin-eluting microspheres.🔍 Two groups: Bridging (n=36) and downstaging (n=17). #TransplantSurgery #Oncology

1/6 🚨 Only 3% post-transplant recurrence in liver transplants after bridging TACE with doxorubicin-eluting microspheres!. Discover new insights from @CVIR_Journal on transplant outcomes for HCC patients using this neoadjuvant technique 🧵. #LiverTransplant #HCC #TACE

6/6 What are your thoughts?. IRs using #AI will replace those who don’t! Save time, get smarter, & become AI enhanced! Be sure to subscribe to our newsletter:. Follow us on LinkedIn: #VIR #iRads @SIRspecialists @SIRRFS.

5/6 📌 Conclusion: University of Miami's endeavor provides a valuable roadmap for institutions aiming to develop standalone IR departments, highlighting vital strategies and potential hurdles. 🔗 Full study: #IRSuccess #HealthcareInnovation #MedTwitter.

4/6 Strategic Initiatives:. 🔹 Separation of IR from diagnostic radiology budgets.🔹 Promotion of interdisciplinary research.🔹 Development of outpatient IR clinics for direct patient engagement. #Research #PatientCare #ClinicManagement.